Accelerate to discover

Back to filter

Related topics

The fastest qPCR thermal cycler in the world

BJS Biotechnologies

Sep 19, 2019

With a thermal ramp rate of up to 10°C per second, the xxpress NGx is the fastest, real-time thermal cycler in the...

Cytek webinar - the new age of spectral flow cytometry

Cytek Biosciences

Sep 9, 2019

The Cytek Aurora flow cytometer has made more than twenty-four color flow cytometry panels possible with only three...

New study resolves helicase dynamics and interactions during DNA replication using C-Trap

LUMICKS

Aug 30, 2019

Researchers from Rockefeller University used a C-Trap optical tweezers – fluorescence microscopy system to observe the...

Low-dose maging in a new preclinical total-body PET/CT scanner

Bruker Biospin

Aug 28, 2019

Ionizing radiation constitutes a health risk to imaging scientists and study animals. Both PET and CT produce ionizing...

Sep 22, 2019

Novel methods to analyze platelet activation with the NovoCyte flow cytometer

Acea Biosciences

Aug 26, 2019

Platelets are of large importance in medicine both for their essential role in hemostasis and thrombosis, as well as...

Assessment of pro-arrhythmic effects using xCELLigence Cardio system and Pluricyte Cardiomyocytes

Acea Biosciences

Aug 21, 2019

The combination of Pluricyte Cardiomyocytes and the xCELLigence RTCA Cardio ECR system enables  detailed ...

Bruker announces acquisition of preclinical and molecular imaging research software provider PMOD

Bruker Biospin

Aug 19, 2019

The PMOD software is widely used for the analysis of positron emission tomography (PET) studies in neurology,...

Sep 22, 2019

Structural variants identified by Oxford Nanopore PromethION sequencing of the human genome

Sage Science

Aug 16, 2019

The BluePippin was used for High Pass DNA size selection prior to library construction. ONT Promethion was used for...

Show all topics (10)

Heterodimeric compounds with dual-targeting active against both HIV and tuberculosis.

Jun 4, 2018

Both HIV and Tuberculosis are considered to be one of the most dangerous infectious diseases in the world. Quite often these two pathogens work in synchrony, making the risk of patient´s death twice as high. To solve this problem researchers from the Engelhardt Institute of Molecular biology in Russia cooperated with the National Institute of Health in the USA. They created compounds with dual activity against both pathogens by creating a heterodimer based on nucleosides. These heterodimers have two active components with two different rates of release based on the speed of their hydrolysis. They tested five of such compounds on HIV and Tuberculosis strain MS-114, which is drug-resistance. Drug-resistance of tuberculosis is one of the main problems in the treatment nowadays.

The compounds were judged based on the ability to inhibit these pathogens. Additionally, a testing on the host tissue was done using NovoCyte. The researchers tested the viability of mammalian lymphoid tissue after treatment. The results show that the heterodimers are non-toxic and non-static towards the cells while maintaining the potency against the pathogens. So far the compound was tested in vivo and ex vitro and seem to be a very promising solution. These results bring interesting insight and novel approach toward treatment of both HIV and Tuberculosis.

Want to know more?

Scientific paper
Application

Related technologies: Conventional flow cytometry

Brand profile

Acea Biosciences

ACEA manufactures xCELLigence impedance-based, label-free, real time cell analysis system and NovoCyte flow cytometers.

Related products

The best in class personalized flow cytometer

show detail

We supply and support Life-Science Technologies in the territory of Central and Eastern Europe.

Czech Republic

Slovakia

Hungary

Poland

Croatia

Slovenia

Serbia

Romania

Bulgaria

Latvia

Lithuania

Estonia

Russia

Ukraine

Belarus

Turkey